作者:Bernard Barlaam、Scott Boiko、Scott Boyd、Hannah Dry、Lakshmaiah Gingipalli、Timothy Ikeda、Tony Johnson、Sameer Kawatkar、Olivier Lorthioir、Andy Pike、Hannah Pollard、Jon Read、Qibin Su、Haiyun Wang、Huimin Wang、Lianghe Wang、Peng Wang、Scott D. Edmondson
DOI:10.1016/j.bmcl.2020.127523
日期:2020.11
Hybridisation of amino-pyrimidine based SYK inhibitors (e.g. 1a) with previously reported diamine-based SYK inhibitors (e.g. TAK-659) led to the identification and optimisation of a novel pyrimidine-based series of potent and selective SYK inhibitors, where the original aminomethylene group was replaced by a 3,4-diaminotetrahydropyran group. The initial compound 5 achieved excellent SYK potency. However
基于氨基嘧啶的SYK抑制剂(例如1a)与先前报道的基于二胺的SYK抑制剂(例如TAK-659)的杂交导致了新型基于嘧啶的有效和选择性SYK抑制剂的鉴定和优化,其中原始的氨基亚甲基基团被3,4-二氨基四氢吡喃基团取代。初始化合物5实现了出色的SYK效能。但是,它具有差的渗透性和适度的激酶选择性。确定了3,4-二氨基四氢吡喃基团的进一步修饰,并通过蛋白质X射线晶体学表征了这些基团与Asp512的相互作用。该系列的进一步优化看到了混合的结果,其中渗透性和激酶选择性增加,并且在该系列中获得了口服生物利用度,但以有效的hERG抑制为代价。